MedPath

Efficacy of Adjunctive Cerebellar Transcranial Alternating Current Stimulation in Negative Symptoms of Schizophrenia

Phase 3
Conditions
Health Condition 1: F209- Schizophrenia, unspecified
Registration Number
CTRI/2023/10/058415
Lead Sponsor
Central Institute of Psychiatry
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1. Diagnosis of Schizophrenia using International Classification of Diseases-11th edition

(ICD-11) (WHO, 2019).

2. Patients giving written informed consent.

3. Right-handed patients.

4. Illness duration of equal to or more than 2 years.

5. The Positive and Negative Syndrome Scale for Schizophrenia (PANSS) with negative

symptoms score of more than 15.

6. Scale for Assessment of Negative Symptoms (SANS) score more than 20.

7. Calgary Depression Scale for Schizophrenia (CDSS) score less than 7.

Exclusion Criteria

1. Presence of co-morbid neurological or other psychiatric disorder(s).

2. Patient with co-morbid substance dependence, except nicotine and caffeine.

3. Patients having any metallic implants in the body.

4. Subjects who have received ECT in past 1 month.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Cerebellar theta tACS results in a change in the negative symptoms at the end of 10 sessions.Timepoint: Improvement in the scores of PANSS, SANS, CGI at the end of 10 sessions(2 weeks) & 6 weeks as compared to baseline.
Secondary Outcome Measures
NameTimeMethod
Changes in the levels of GABA, Glutamate, Glutamine, NAA & NAAG in cerebellum using Proton MR Spectroscopy post theta tACS administration to cerebellum.Timepoint: Baseline, at the end of 10 theta tACS sessions(2 weeks).
© Copyright 2025. All Rights Reserved by MedPath